SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys technical rebound and breakout attempt are drawing attention, with traders debating whether the shares can sustain upward momentum or will meet resistance again. Bulls also cite stronger parks and streaming performance in the quarterly results, while skeptics point to the stocks prolonged range-bound history and risk of another pullback.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias third-quarter results and higher full-year revenue guidance are driving discussion, with traders noting continued LUPKYNIS growth and profitability. Despite the solid report, the share-price decline and uncertainty over the earnings call and undisclosed AUR200 indications have frustrated investors.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned Q4 BLA submission for CAN-2409 in localized prostate cancer and upcoming SITC pipeline data. Bulls see the clinical and regulatory milestones as potential catalysts, while skeptics point to the steep decline, CEO share sales, limited transparency, possible dilution and uncertainty about filing timing; some also blame broader biotech weakness and thin trading.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys Q3 results and upbeat Q4 outlook are driving attention: premium subscriber growth and stronger-than-expected margin and profit guidance outweighed misses on revenue and EPS. Traders are debating the sharp rally despite those misses, with bulls emphasizing subscriber momentum, improving advertising growth, and the forward outlook while skeptics point to higher expenses and weaker cash flow.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing attention after a sharp pullback from a strong run-up ahead of earnings. Traders are split between optimism about merchant growth and AI-driven commerce, including Metas Muse integration, and concerns about valuation, fading momentum, and broader weakness in software stocks.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

ALAB is drawing attention amid a sharp pullback in AI and semiconductor stocks, with traders pointing to concern over AI spending and reports questioning OpenAIs revenue outlook as possible pressure on the sector. Bulls call the selloff an overreaction and are buying the dip, while bears argue the stocks high valuation leaves it vulnerable to further declines.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could weaken in 2027 has sparked concerns about pricing and CorMedixs largest revenue driver, contributing to a sharp selloff. Traders are divided over the impact: some see a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS reimbursement estimates as a reason the reaction may be excessive.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity and warrant offering, alongside its Elisity acquisition, has put dilution and capital allocation at the center of the discussion as shares have sold off. Bulls see the financing and acquisitions as building a broader quantum platform, while critics question shareholder costs and execution; a Google quantum breakthrough has also lifted sector optimism, though traders disagree on whether that can overcome IONQ-specific concerns.

NEAR Protocol (NEAR) is a cryptocurrency launched in 2020. NEAR Protocol has a current supply of 1,310,395,414. The last known price of NEAR Protocol is 4.30157975 USD and is up 6.10 over the last 24 hours. It is currently trading on 688 active market(s) with $1,245,620,491.67 traded over the last 24 hours. More information can be found at https://near.org/.

Near

Traders are focused on a NEAR governance vote that they say could reduce token inflation, with some viewing the votes close as a potential catalyst. Sentiment is mixed: some are accumulating in anticipation, while others expect further weakness amid Bitcoin-linked selling and liquidation concerns.

Pyth Network (PYTH) is a cryptocurrency launched in 2021and operates on the Solana platform. Pyth Network has a current supply of 9,999,981,857.422035 with 7,874,958,864.894765 in circulation. The last known price of Pyth Network is 0.06503621 USD and is up 3.48 over the last 24 hours. It is currently trading on 450 active market(s) with $50,940,939.77 traded over the last 24 hours. More information can be found at https://pyth.network/.

Pyth Network

PYTH is drawing attention for its market-data and real-world-asset narrative, especially its Nasdaq data distribution and a DAO rule directing product revenue toward PYTH accumulation; traders are also watching a teased Pyth announcement. Sentiment is mostly bullish on adoption and a price rebound, though some posts question the rallys staying power and cite token unlocks and selling pressure as risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of ‘Strongest Years Ever’ After Q3 Earnings Beat

Equity

Regeneron reported a 36% surge in Q3 revenue to $5.12 billion, well above Wall Street estimates of $4.56 billion, according to Fiscal.ai


SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3

Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.

IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ – What’s Driving The Fall?

Iovance reported updated results from its Phase 2 IOV-LUN-202 trial evaluating Lifileucel in patients with metastatic non-squamous non-small-cell lung cancer.


SLS Stock’s Big AML Trial Milestone Sparks A Selloff — What’s Fueling Retail’s ‘Extremely Bullish’ Bets?

Retail bulls discussed buying the dip and a potential buyout, while others also challenged survival estimates.

VKTX Stock Slides Overnight After Q3 Loss: CEO’s Obesity Drug Launch Timeline Frustrates Retail

CEO Brian Lian said a potential launch of obesity drug VK2735 remained about 2 and a half years away.

Why Did IOVA Stock Jump Over 10% After-Hours Today? 

Iovance will share positive Phase 2 results for Lifileucel on Thursday, along with a precision-medicine update.

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know

Genmab’s Petosemtamab, when combined with Merck’s blockbuster cancer therapy Keytruda, reduced the risk of death by 50% compared with Keytruda alone.


ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside

BEAM-301 is a one-time liver-targeted treatment designed to correct a common genetic error that causes glycogen storage disease type Ia, or GSDIa.


Artiva Scraps Development Of Lead Drug Candidate After Patient Deaths — ARTV Stock Heads For Worst Session In Over 18 Months

Artiva said it would reduce its workforce by about 94% and has hired Leerink Partners to explore strategic options, including a merger and asset sale.


SPDR Series Trust - State Street SPDR S&P Biotech ETF

Bearish Sentiment

<ul class="summary-bullets"><li>Adjusted EPS shot up 70% to $20.07.</li><li>U.S. sales of Eylea HD, its higher-dose injectable treatment for certain retinal diseases, jumped 62% to $699 million.</li><li>Regeneron’s collaboration revenue from Sanofi surged 68% to $2.72 billion, driven by Dupixent sales.</li></ul>Shares of Regeneron Pharmaceuticals (REGN) gained more than 8% in premarket trading on Friday, after the biotechnology firm reported stronger-than-expected third-quarter earnings, driven by growing demand for its eye treatments and higher collaboration revenue from Sanofi.If the levels hold after the opening bell, <a class="mention" data-mention="$REGN" data-symbol-id="REGN" href="https://stocktwits.com/symbol/REGN" target="_blank">REGN shares</a> would jump to their highest levels since October 2024.<h2 class="st-heading-2">Eye Treatment, Sanofi Partnership Drive Growth</h2>Regeneron reported a 36% surge in Q3 revenue to $5.12 billion, well above Wall Street estimates of $4.56 billion, according to Fiscal.ai. Adjusted earnings per share (EPS) shot up 70% to $20.07, also exceeding consensus estimates of $16.25.CFO Christopher Fenimore attributed the Q3 beat to strong sales performance across its drug portfolio and higher collaboration revenue from Sanofi.“Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever,” Fenimore said.U.S. sales of Eylea HD, its higher-dose injectable treatment for certain retinal diseases, jumped 62% to $699 million. However, sales of the original Eylea fell 41% as patients switched to the newer version.Regeneron’s collaboration revenue from Sanofi surged 68% to $2.72 billion, driven by strong demand for Dupixent, an inflammation treatment. Earlier this month, Regeneron and Sanofi expanded their partnership to develop four long-acting antibody treatments, with Regeneron receiving $1 billion upfront and becoming eligible for another $7 billion in future milestone payments.<h2 class="st-heading-2">FDA Decision On Cemdisiran Expected Next Month</h2>Regeneron has approximately 50 product candidates in clinical development, covering cancer, obesity, immune disorders and other diseases. The company expects a U.S. Food and Drug Administration (FDA) decision on Cemdisiran for generalized myasthenia gravis, a condition that causes muscle weakness, in November.It ended September with approximately $18.86 billion in cash and marketable securities.Regeneron raised its full-year research and development spending forecast to $6.60 billion - $6.74 billion and capital expenditure guidance to $1.05 billion - $1.10 billion.<h2 class="st-heading-2">Retail Says REGN Stock Is ‘Cheap’</h2>Retail sentiment surrounding REGN on Stocktwits remained ‘bullish’ over the past 24 hours.<img src="https://news.stocktwits-cdn.com/REGN_04f901a562.png" alt="REGN.png">One user called the stock cheap given the company’s underlying assets.<stembedurl>https://stocktwits.com/OffHisGame88/message/667738421</stembedurl>REGN shares are up nearly 15% so far in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/astra-zeneca-ceo-sees-over-20b-potential-from-2027-drug-trial-readouts-azn-stock-eyes-breakout/cZUhAwOR9Th">&nbsp;AstraZeneca CEO Sees Over $20B Potential From 2027 Drug Trial Readouts – AZN Stock Eyes Breakout After Q3 Earnings Beat</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron reported a 36% surge in Q3 revenue to $5.12 billion, well above Wall Street estimates of $4.56 billion, according to Fiscal.ai

Regeneron Pharmaceuticals, Inc.

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$155.98
Prev Close	$157.79
Open	$156.68
Dividend Yield	N/A
50-Day Moving Average	$156.60
Beta	N/A
Avg. Volume	8.47M
PE Ratio	N/A

52-Week High	$169.89
52-Week Low	$106.30
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

XBI Fundamentals